Wellspect
Wellspect, a leading name in the medical technology industry, is headquartered in Sweden (SE) and operates extensively across Europe and North America. Founded in 2014, the company has quickly established itself as a pioneer in innovative healthcare solutions, particularly in the fields of urology and continence care. Wellspect is renowned for its core products, including the LoFric range of intermittent catheters, which are distinguished by their unique hydrophilic coating that enhances comfort and reduces the risk of urinary tract infections. The company’s commitment to quality and patient-centric design has positioned it as a trusted partner in healthcare, achieving notable recognition for its contributions to improving patient outcomes. With a focus on research and development, Wellspect continues to lead the way in advancing medical technologies that empower individuals to manage their health with confidence.
DitchCarbon Score
How does Wellspect's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Wellspect's score of 36 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Wellspect's reported carbon emissions
Wellspect AB, headquartered in Sweden, has set ambitious climate commitments aimed at achieving net-zero greenhouse gas (GHG) emissions across its value chain by 2045. Although specific carbon emissions data for the most recent year is not available, the company has established significant reduction targets based on a 2021 baseline. For the near term, Wellspect aims to reduce absolute Scope 1 and 2 GHG emissions by 80% by 2030. Additionally, it plans to cut absolute Scope 3 emissions—covering upstream transportation, waste generated in operations, and upstream leased assets—by 42% within the same timeframe. Furthermore, Wellspect is committed to ensuring that 74.9% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation, will have science-based targets by 2026. In the long term, Wellspect has set a target to reduce absolute Scope 1 and 2 emissions by 95% and Scope 3 emissions by 90% by 2045. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to contribute to limiting global warming to 1.5°C. Wellspect's proactive approach to sustainability reflects its commitment to addressing climate change and reducing its environmental impact within the healthcare equipment and supplies sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Wellspect is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
